Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. Among authors: jones j. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
Spotlight on alemtuzumab.
Jones JL, Coles AJ. Jones JL, et al. Int MS J. 2009 Sep;16(3):77-81. Int MS J. 2009. PMID: 19878629 Review.
New treatment strategies in multiple sclerosis.
Jones JL, Coles AJ. Jones JL, et al. Exp Neurol. 2010 Sep;225(1):34-9. doi: 10.1016/j.expneurol.2010.06.003. Epub 2010 Jun 12. Exp Neurol. 2010. PMID: 20547155 Review.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Azzopardi L, Thompson SA, Harding KE, Cossburn M, Robertson N, Compston A, Coles AJ, Jones JL. Azzopardi L, et al. Among authors: jones jl. J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):795-8. doi: 10.1136/jnnp-2013-307042. Epub 2013 Dec 24. J Neurol Neurosurg Psychiatry. 2014. PMID: 24368840
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.
Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, May K, Button T, Azzopardi L, Kousin-Ezewu O, Fahey MT, Jones J, Compston DA, Coles A. Tuohy O, et al. Among authors: jones j. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):208-15. doi: 10.1136/jnnp-2014-307721. Epub 2014 May 21. J Neurol Neurosurg Psychiatry. 2015. PMID: 24849515 Clinical Trial.
Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
Willis MD, Hope-Gill B, Flood-Page P, Joseph F, Needham E, Jones J, Coles A, Robertson NP. Willis MD, et al. Among authors: jones j. Mult Scler. 2018 Nov;24(13):1779-1782. doi: 10.1177/1352458518790391. Epub 2018 Oct 11. Mult Scler. 2018. PMID: 30307364
Campath-1H treatment of multiple sclerosis.
Jones JL, Coles AJ. Jones JL, et al. Neurodegener Dis. 2008;5(1):27-31. doi: 10.1159/000109935. Neurodegener Dis. 2008. PMID: 18075272 Review.
14,331 results
You have reached the last available page of results. Please see the User Guide for more information.